Pharmaceutical News and Articles

Insulin Nasal Spray Reaches Alzheimer's Targets, Brain Scans Show

THURSDAY, July 24, 2025 Insulin delivered by nasal spray might be a potential treatment for Alzheimer s disease, a new study says. An insulin nasal spray effect

The Many Faces of Parkinson’s: Symptoms, Treatment, and How To Manage It

THURSDAY, July 24, 2025 About 90,000 people are diagnosed with Parkinson s disease (PD) each year one person every six minutes. While most people associate PD w

FDA Approves Anzupgo (delgocitinib) Cream for the Treatment of Chronic Hand Eczema

Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping

Avidity Biosciences, Inc. (Nasdaq RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conj

Endurance Athletes Could Be At Increased Risk Of Dangerous Heart Scarring, Researchers Say

WEDNESDAY, July 23, 2025 Apparently healthy endurance athletes could have scar tissue building up in their heart, increasing their risk of dangerous abnormal he

Tuna Recalled in Seven States Over Listeria Fears

WEDNESDAY, July 23, 2025 Two types of tuna sold in seven states are being recalled due to listeria concerns. The first recall affects tuna salad and ready-to-ea

USPSTF Guidelines of Little Value for Estimating Preeclampsia Risk in Those at Moderate Risk

Moderate U.S. Preventive Services Task Force (USPSTF) preeclampsia risk factors have little value for estimating the risk for preeclampsia, according to a study

GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with metformin,

Cancer Anxiety Impacts Family Members of Those Diagnosed With Cancer

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. The survey was conducted in May 2025 online (978 participants) and by telephone (30 pa

Study Compares Benefits, Harms of Treatments for Chronic Hives

Omalizumab and remibrutinib may be the most effective treatments for reducing hives, itch, and swelling with chronic urticaria, according to a study published o